<p>澳大利亚市场正经历一些波动，期货显示 ASX 200 略有下滑，这主要受到国际贸易不确定性持续影响。尽管出现这些波动，投资者仍在各个领域寻找机会，包括常被忽视的便士股票领域。虽然 “便士股票” 这个术语可能显得过时，但这些较小或较新的公司在稳健的财务支持下，能够提供独特的增长和价值机会。</p>
<h3>澳大利亚十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$2.2519 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$1.4901 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$11.4 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$7383 万</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$3.9316 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$1.1642 亿</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$1.6608 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$7.8326 亿</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$6.9978 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$2.7221 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们 ASX 便士股票筛选器的完整 1000 只股票列表。</p>
<p>在这里，我们突出了一部分我们偏好的股票。</p>
<h2>Aroa Biosurgery (ASX:ARX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aroa Biosurgery Limited 开发、制造并销售用于伤口和软组织修复的医疗设备，采用细胞外基质技术，市场覆盖美国及国际，市值为 A$1.759 亿。</p>
<p><strong>运营：</strong> 收入细分：Aroa Biosurgery Limited 未报告具体的收入细分。</p>
<p><strong>市值：</strong> A$1.759 亿</p>
<p>Aroa Biosurgery 在销售方面取得了显著进展，截止 2025 年 3 月 31 日的年度销售额达到新西兰元 8470 万，较去年有所增长。尽管净亏损为新西兰元 381 万，但这标志着相较于之前亏损的改善。该公司无债务，现金状况良好，短期资产显著超过负债，确保了超过三年的稳定财务运行。最近的临床证据显示，其 Endoform Natural 产品在治疗静脉性腿部溃疡方面的效果优于竞争对手，可能改善患者结果并降低伤口护理管理的成本。</p>
<ul>
<li>点击探索我们在 Aroa Biosurgery 财务健康报告中的详细分析。</li>
<li>查看 Aroa Biosurgery 的盈利增长报告，以了解分析师对其表现的预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis"/></p>
<p>ASX:ARX 财务状况分析截至 2025 年 6 月</p>
<h2>Baby Bunting Group (ASX:BBN)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Baby Bunting Group Limited 在澳大利亚和新西兰经营母婴商品零售，市值为 A$2.3341 亿。</p>
<p><strong>运营：</strong> 该公司从其专业零售部门产生 A$4.969 亿的收入。</p>
<p><strong>市值：</strong> A$2.3341 亿</p>
<p>Baby Bunting Group 的财务状况复杂，市值为 A$2.3341 亿，专业零售部门收入为 A$4.969 亿。该公司面临挑战，例如过去一年盈利增长为负，利润率下降，目前为 1.2%。尽管存在这些问题，Baby Bunting 的净债务与股本比率为 8.6%，且债务由运营现金流 177.9% 良好覆盖。然而，短期资产无法覆盖长期负债（A$1.32 亿），EBIT 的利息覆盖率低至 2.2 倍，表明未来可能面临财务压力。</p>
<ul>
<li>点击这里深入了解 Baby Bunting Group 的完整分析健康报告。</li>
<li>在我们的增长报告中探索 Baby Bunting Group 的分析师预测。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:BBN 收入与支出分析截至 2025 年 6 月</p>
<h2>COSOL (ASX:COS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> COSOL Limited 及其子公司在亚太地区、北美、欧洲、中东、非洲及全球提供信息技术服务，市值为 A$1.4286 亿。</p>
<p><strong>运营：</strong> 该公司主要从亚太地区运营中产生收入，贡献 A$9875 万，北美活动增加 A$1226 万。</p>
<p><strong>市值：</strong> A$1.4286 亿</p>
<p>COSOL Limited 市值为 A$1.4286 亿，财务健康状况复杂。以 16 倍的市盈率交易，并提供高质量的收益，相较于同行具有潜在价值。然而，其短期资产（A$3230 万）无法覆盖长期负债（A$4070 万），净利润率从 9.5% 下降至 8.1%。该公司的债务由运营现金流 25% 良好覆盖，但 3.04% 的股息收益率并未得到自由现金流的支持。最近被纳入 S&amp;P/ASX All Ordinaries Index，突显其在市场上的日益认可。</p>
<ul>
<li>点击这里阅读我们的资产负债表健康报告，深入了解 COSOL 的表现。</li>
<li>通过查看我们的增长报告，获取 COSOL 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis"/></p>
<p>ASX:COS 债务与股本历史分析截至 2025 年 6 月</p>
<h2>让它发生</h2>
<ul>
<li>点击这里，揭示我们 ASX 便士股票筛选器中隐藏的 1,000 个宝藏股票。</li>
<li>准备好不同的投资方式了吗？特朗普的石油繁荣已经到来——管道准备好获利。发现 22 只乘风而起的美国股票。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

林赛

<p>澳大利亚市场因国际贸易不确定性面临 ASX 200 的轻微下跌。投资者正在探索便士股票，这些股票可能提供增长机会。值得注意的便士股票包括 Lindsay Australia、CTI Logistics 和 Aroa Biosurgery，后者尽管出现净亏损，但销售增长显著。Baby Bunting Group 面临利润率下降的挑战，而 COSOL Limited 的财务状况则表现不一，但在 S&P/ASX All Ordinaries Index 中受到认可。总体而言，便士股票领域仍然是投资者在市场波动中寻求价值的重点</p>

<p>The Australian market is experiencing some turbulence, with futures indicating a slight decline for the ASX 200, largely influenced by ongoing international trade uncertainties. Despite these fluctuations, investors continue to seek opportunities in various sectors, including the often-overlooked realm of penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities for growth and value when supported by solid financials.</p>
<div class="lb-trans"><p>澳大利亚市场正经历一些波动，期货显示 ASX 200 略有下滑，这主要受到国际贸易不确定性持续影响。尽管出现这些波动，投资者仍在各个领域寻找机会，包括常被忽视的便士股票领域。虽然 “便士股票” 这个术语可能显得过时，但这些较小或较新的公司在稳健的财务支持下，能够提供独特的增长和价值机会。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亚十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$225.19M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$149.01M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$1.14B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$73.83M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$393.16M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$116.42M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$166.08M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$783.26M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$699.78M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$272.21M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lindsay Australia (ASX:LAU)</td>
<td>A$0.71</td>
<td>A$2.2519 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.85</td>
<td>A$1.4901 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Accent Group (ASX:AX1)</td>
<td>A$1.90</td>
<td>A$11.4 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$1.565</td>
<td>A$7383 万</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.55</td>
<td>A$3.9316 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.61</td>
<td>A$1.1642 亿</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bisalloy Steel Group (ASX:BIS)</td>
<td>A$3.50</td>
<td>A$1.6608 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$2.33</td>
<td>A$7.8326 亿</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$2.99</td>
<td>A$6.9978 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$3.29</td>
<td>A$2.7221 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们 ASX 便士股票筛选器的完整 1000 只股票列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出了一部分我们偏好的股票。</p>
</div><h2>Aroa Biosurgery (ASX:ARX)</h2>
<div class="lb-trans"><h2>Aroa Biosurgery (ASX:ARX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$175.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aroa Biosurgery Limited 开发、制造并销售用于伤口和软组织修复的医疗设备，采用细胞外基质技术，市场覆盖美国及国际，市值为 A$1.759 亿。</p>
</div><p><strong>Operations:</strong> Revenue Segments: No specific revenue segments have been reported for Aroa Biosurgery Limited.</p>
<div class="lb-trans"><p><strong>运营：</strong> 收入细分：Aroa Biosurgery Limited 未报告具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> A$175.9M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.759 亿</p>
</div><p>Aroa Biosurgery has demonstrated notable progress, with sales reaching NZ$84.7 million for the year ending March 31, 2025, reflecting an increase from the previous year. Despite a net loss of NZ$3.81 million, this marks an improvement from prior losses. The company is debt-free and maintains a strong cash position with short-term assets surpassing liabilities significantly, ensuring a stable financial runway for over three years. Recent clinical evidence highlights the efficacy of its Endoform Natural product in treating venous leg ulcers more effectively than competitors, potentially enhancing patient outcomes and reducing costs in wound care management.</p>
<div class="lb-trans"><p>Aroa Biosurgery 在销售方面取得了显著进展，截止 2025 年 3 月 31 日的年度销售额达到新西兰元 8470 万，较去年有所增长。尽管净亏损为新西兰元 381 万，但这标志着相较于之前亏损的改善。该公司无债务，现金状况良好，短期资产显著超过负债，确保了超过三年的稳定财务运行。最近的临床证据显示，其 Endoform Natural 产品在治疗静脉性腿部溃疡方面的效果优于竞争对手，可能改善患者结果并降低伤口护理管理的成本。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report.</li>
<li>Examine Aroa Biosurgery's earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Aroa Biosurgery 财务健康报告中的详细分析。</li>
<li>查看 Aroa Biosurgery 的盈利增长报告，以了解分析师对其表现的预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/fa5ec572-df92-499c-a8b8-32f54e806608/chart/financial-position-analysis"/></p>
<p>ASX:ARX Financial Position Analysis as at Jun 2025</p>
<div class="lb-trans"><p>ASX:ARX 财务状况分析截至 2025 年 6 月</p>
</div><h2>Baby Bunting Group (ASX:BBN)</h2>
<div class="lb-trans"><h2>Baby Bunting Group (ASX:BBN)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Baby Bunting Group Limited operates as a retailer of maternity and baby goods in Australia and New Zealand, with a market cap of A$233.41 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Baby Bunting Group Limited 在澳大利亚和新西兰经营母婴商品零售，市值为 A$2.3341 亿。</p>
</div><p><strong>Operations:</strong> The company generates A$496.90 million in revenue from its specialty retail segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其专业零售部门产生 A$4.969 亿的收入。</p>
</div><p><strong>Market Cap:</strong> A$233.41M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$2.3341 亿</p>
</div><p>Baby Bunting Group's financial position is mixed, with a market cap of A$233.41 million and revenue of A$496.90 million from its specialty retail segment. The company faces challenges, such as negative earnings growth over the past year and declining profit margins, currently at 1.2%. Despite these issues, Baby Bunting maintains a satisfactory net debt to equity ratio of 8.6%, with debt well covered by operating cash flow at 177.9%. However, short-term assets do not cover long-term liabilities (A$132 million), and interest coverage by EBIT is low at 2.2x, indicating potential financial strain ahead.</p>
<div class="lb-trans"><p>Baby Bunting Group 的财务状况复杂，市值为 A$2.3341 亿，专业零售部门收入为 A$4.969 亿。该公司面临挑战，例如过去一年盈利增长为负，利润率下降，目前为 1.2%。尽管存在这些问题，Baby Bunting 的净债务与股本比率为 8.6%，且债务由运营现金流 177.9% 良好覆盖。然而，短期资产无法覆盖长期负债（A$1.32 亿），EBIT 的利息覆盖率低至 2.2 倍，表明未来可能面临财务压力。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Baby Bunting Group.</li>
<li>Explore Baby Bunting Group's analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Baby Bunting Group 的完整分析健康报告。</li>
<li>在我们的增长报告中探索 Baby Bunting Group 的分析师预测。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/4c89021c-58a0-4f55-b9f7-7339012f2ecc/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:BBN Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>ASX:BBN 收入与支出分析截至 2025 年 6 月</p>
</div><h2>COSOL (ASX:COS)</h2>
<div class="lb-trans"><h2>COSOL (ASX:COS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> COSOL Limited, along with its subsidiaries, offers information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and globally with a market cap of A$142.86 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> COSOL Limited 及其子公司在亚太地区、北美、欧洲、中东、非洲及全球提供信息技术服务，市值为 A$1.4286 亿。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Asia Pacific operations, contributing A$98.75 million, and North American activities, adding A$12.26 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要从亚太地区运营中产生收入，贡献 A$9875 万，北美活动增加 A$1226 万。</p>
</div><p><strong>Market Cap:</strong> A$142.86M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.4286 亿</p>
</div><p>COSOL Limited, with a market cap of A$142.86 million, demonstrates mixed financial health. Trading at a value price-to-earnings ratio of 16x and offering high-quality earnings, it presents potential value compared to peers. However, its short-term assets (A$32.3M) do not cover long-term liabilities (A$40.7M), and net profit margins have declined from 9.5% to 8.1%. The company's debt is well covered by operating cash flow at 25%, but the dividend yield of 3.04% isn't supported by free cash flows. Recent inclusion in the S&amp;P/ASX All Ordinaries Index highlights its growing recognition in the market.</p>
<div class="lb-trans"><p>COSOL Limited 市值为 A$1.4286 亿，财务健康状况复杂。以 16 倍的市盈率交易，并提供高质量的收益，相较于同行具有潜在价值。然而，其短期资产（A$3230 万）无法覆盖长期负债（A$4070 万），净利润率从 9.5% 下降至 8.1%。该公司的债务由运营现金流 25% 良好覆盖，但 3.04% 的股息收益率并未得到自由现金流的支持。最近被纳入 S&amp;P/ASX All Ordinaries Index，突显其在市场上的日益认可。</p>
</div><ul>
<li>Get an in-depth perspective on COSOL's performance by reading our balance sheet health report here.</li>
<li>Gain insights into COSOL's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里阅读我们的资产负债表健康报告，深入了解 COSOL 的表现。</li>
<li>通过查看我们的增长报告，获取 COSOL 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/4ecb08b3-3f0d-4b42-8e82-36db33a9e686/chart/debt-equity-history-analysis"/></p>
<p>ASX:COS Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>ASX:COS 债务与股本历史分析截至 2025 年 6 月</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Reveal the 1,000 hidden gems among our ASX Penny Stocks screener with a single click here.</li>
<li>Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里，揭示我们 ASX 便士股票筛选器中隐藏的 1,000 个宝藏股票。</li>
<li>准备好不同的投资方式了吗？特朗普的石油繁荣已经到来——管道准备好获利。发现 22 只乘风而起的美国股票。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

2025 年 6 月值得关注的 ASX 便士股